Kaneka files patent infringement proceedings in France and Germany in the field of coenzyme Q10 against companies in France, Germany and China

News Release

Kaneka files patent infringement proceedings in France and Germany in the field of coenzyme Q10 against companies in France, Germany and China

KANEKA CORPORATION
October 29, 2010
Kaneka Corporation (headquarters: Osaka, Japan; President: Mr. Kimikazu Sugawara) has instituted further steps in its existing patent enforcement programme to enforce its proprietary rights in those countries in which its patents relating to coenzyme Q10 are in force. An objective of this programme is to protect Kaneka’s intellectual property rights in its coenzyme Q10 products.

“Kaneka has been the leading developer of many significant improvements in the production and quality of coenzyme Q10” said Mr. Yoshimi Uchida, General Manager of QOL Division at Kaneka. “We will vigorously defend these rights and immediately initiate court proceedings to enforce our intellectual property rights. We are taking these steps to protect the results of our research and development and to avoid the unlawful use of Kaneka’s innovations.”

Kaneka filed legal proceedings in 2009 against Xiamen Kingdomway Vitamin Inc. and Pacific Rainbow Inc. in the United States District Court for the Central District of California alleging infringement of a patent relating to the form of coenzyme Q10 known as ubiquinol (marketed by
Kaneka as Kaneka QH™). The parties reached a settlement of this case, pursuant to which Kingdomway and Pacific Rainbow agreed to discontinue their ubiquinol products within the United States.

As one of the subsequent steps in this programme, Kaneka has now filed legal proceedings in the Tribunal de Grand Instance of Paris, France and the Düsseldorf Regional Court, Germany. The patent, European Patent No. 1 466 983, relates to the manufacture of coenzyme Q10. The legal proceedings are against Chinese manufacturers and distributors of coenzyme Q10, as well as their European
distributors. In the legal proceedings, Kaneka seeks damages and an injunction against future infringement of its patent.

News Release list
Page Top